It is a multifactorial therapy that targets several IPF-associated targets concurrently ... of detail needed to understand the effects and map this to patient outcomes. “By focusing on localised ...

The study, published in the European Respiratory Journal, used advanced spatial mapping techniques to compare healthy lung tissues and tissues from patients with fatal IPF. The researchers ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Roughly one in five (21 percent) of idiopathic pulmonary fibrosis (IPF) deaths might be related ... created a detailed map of the location and identity of individual cells in the adult lung ...

Its pipeline is currently headed by VP01 (also known as C21), billed as a first-in-class oral angiotensin II type 2 receptor (AT2R) agonist, which is in phase 2 development for IPF and phase 3 for ...

Idiopathic pulmonary fibrosis (IPF) is a fatal disease that's all the more difficult for patients because of a lack of awareness and investment in supporting people with the condition. In the week ...

We believe these results, particularly the safety data, underscore GRI-0621’s potential to provide a much needed safe and effective treatment option for the treatment of IPF, where there remains ...